WallStreetZenWallStreetZen

NASDAQ: CDTX
Cidara Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CDTX

Based on 9 analysts offering 12 month price targets for Cidara Therapeutics Inc

Min Forecast
$53.00-75.95%
Avg Forecast
$156.89-28.8%
Max Forecast
$200.00-9.24%

Should I buy or sell CDTX stock?

Based on 9 analysts offering ratings for Cidara Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 44.44%
Buy
5 analysts 55.56%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CDTX stock forecasts and price targets.

CDTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-07
lockedlocked$00.00+00.00%2025-11-07
lockedlocked$00.00+00.00%2025-10-21
lockedlocked$00.00+00.00%2025-10-16
lockedlocked$00.00+00.00%2025-10-10
WBB Securities
Top 26%
75
Strong BuyMaintains$199.00-9.69%2025-10-09
JMP Securities
Top 1%
100
BuyMaintains$173.00-21.49%2025-10-03
Guggenheim
Top 2%
99
Strong BuyMaintains$167.00-24.21%2025-09-25Find out why
HC Wainwright & Co.
Top 5%
96
BuyMaintains$53.00-75.95%2025-06-24

1 of 1

Forecast return on equity

Is CDTX forecast to generate an efficient return?

Company
5.21%
Industry
259.27%
Market
228.52%
CDTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CDTX forecast to generate an efficient return on assets?

Company
4.25%
Industry
90.14%
CDTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CDTX earnings per share forecast

What is CDTX's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$8.30
Avg 2 year Forecast
-$6.40
Avg 3 year Forecast
-$6.48

CDTX revenue forecast

What is CDTX's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$8.6M
Avg 3 year Forecast
$10.2M

CDTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CDTX$220.36$156.89-28.80%Strong Buy
RYTM$104.60$120.50+15.20%Strong Buy
KRYS$234.13$213.17-8.95%Buy
ABVX$114.51$120.09+4.87%Strong Buy
MRUS$96.14$96.33+0.20%Hold
View Top Biotech Stocks

Cidara Therapeutics Stock Forecast FAQ

Is Cidara Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: CDTX) stock is to Strong Buy CDTX stock.

Out of 9 analysts, 4 (44.44%) are recommending CDTX as a Strong Buy, 5 (55.56%) are recommending CDTX as a Buy, 0 (0%) are recommending CDTX as a Hold, 0 (0%) are recommending CDTX as a Sell, and 0 (0%) are recommending CDTX as a Strong Sell.

If you're new to stock investing, here's how to buy Cidara Therapeutics stock.

What is CDTX's earnings growth forecast for 2025-2027?

(NASDAQ: CDTX) Cidara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Cidara Therapeutics's earnings in 2025 is -$184,738,000.On average, 11 Wall Street analysts forecast CDTX's earnings for 2025 to be -$260,905,908, with the lowest CDTX earnings forecast at -$282,224,946, and the highest CDTX earnings forecast at -$196,747,584. On average, 10 Wall Street analysts forecast CDTX's earnings for 2026 to be -$201,340,876, with the lowest CDTX earnings forecast at -$309,954,471, and the highest CDTX earnings forecast at -$133,695,925.

In 2027, CDTX is forecast to generate -$203,815,154 in earnings, with the lowest earnings forecast at -$302,559,931 and the highest earnings forecast at -$133,695,925.

What is CDTX's revenue growth forecast for 2025-2027?

(NASDAQ: CDTX) Cidara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Cidara Therapeutics's revenue in 2025 is $0.On average, 11 Wall Street analysts forecast CDTX's revenue for 2025 to be $0, with the lowest CDTX revenue forecast at $0, and the highest CDTX revenue forecast at $0. On average, 10 Wall Street analysts forecast CDTX's revenue for 2026 to be $270,284,272, with the lowest CDTX revenue forecast at $0, and the highest CDTX revenue forecast at $990,340,187.

In 2027, CDTX is forecast to generate $321,687,644 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,360,821,734.

What is CDTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CDTX) forecast ROA is 4.25%, which is lower than the forecast US Biotechnology industry average of 90.14%.

What is CDTX's Price Target?

According to 9 Wall Street analysts that have issued a 1 year CDTX price target, the average CDTX price target is $156.89, with the highest CDTX stock price forecast at $200.00 and the lowest CDTX stock price forecast at $53.00.

On average, Wall Street analysts predict that Cidara Therapeutics's share price could fall to $156.89 by Nov 7, 2026. The average Cidara Therapeutics stock price prediction forecasts a potential downside of 28.8% from the current CDTX share price of $220.36.

What is CDTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CDTX) Cidara Therapeutics's current Earnings Per Share (EPS) is -$10.63. On average, analysts forecast that CDTX's EPS will be -$8.30 for 2025, with the lowest EPS forecast at -$8.98, and the highest EPS forecast at -$6.26. On average, analysts forecast that CDTX's EPS will be -$6.40 for 2026, with the lowest EPS forecast at -$9.86, and the highest EPS forecast at -$4.25. In 2027, CDTX's EPS is forecast to hit -$6.48 (min: -$9.62, max: -$4.25).

What is CDTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CDTX) forecast ROE is 5.21%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.